Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy

World Journal of Gastroenterology

Volumn 20, Issue 47, 2014, Pages 18013-18021

  Zhu, Rong ^a,b   Chen, Kan ^a   Zheng, Yuan Yuan ^a   Zhang, Hua Wei ^a   Wang, Jun Shan ^a   Xia, Yu Jing ^a   Dai, Wei Qi ^a   Wang, Fan ^a   Shen, Miao ^a   Cheng, Ping ^a   Zhang, Yan ^a   Wang, Cheng Fen ^a   Yang, Jing ^a   Li, Jing Jing ^a   Lu, Jie ^a   Zhou, Ying Qun ^a   Guo, Chuan Yong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Adult; Eradication; Helicobacter pylori; Meta analysis; Probiotics

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CAUCASIAN; DIARRHEA; DRUG EFFICACY; EPIGASTRIC PAIN; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; META ANALYSIS; METALLIC TASTE; NAUSEA; NONHUMAN; RATING SCALE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TASTE DISORDER; VOMITING; DRUG COMBINATION; DRUG EFFECTS; ETHNOLOGY; HELICOBACTER INFECTIONS; MICROBIOLOGY; ODDS RATIO; PATHOGENICITY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ODDS RATIO; PROBIOTICS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84919723866     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i47.18013     Document Type: Article

References (37)

1. Bartnik W. Clinical aspects of Helicobacter pylori infection. Pol Arch Med Wewn 2008; 118: 426-430 [PMID: 18714738]
2. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16 : 167-180 [PMID: 11860399 DOI: 10.1046/j.1365-2036.2002.01169.x]
3. Perri F, Qasim A, Marras L, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003; 8 Suppl 1: 53-60
4. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26 : 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]
5. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603 DOI: 10.1136/gut.2003.022111]
6. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
7. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 930-935 [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0]
8. Praitano MM, Iacono S, Francavilla R. Probiotics and Helicobacter pylori infection. Medicina Universitaria 2012; 14 : 217-223
9. Franceschi F, Cazzato A, Nista EC, Scarpellini E, Roccarina D, Gigante G, Gasbarrini G, Gasbarrini A. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 2007; 12 Suppl 2: 59-63 [PMID: 17991178 DOI: 10.1111/j.1523-5378.2007.00565.x]
10. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155-168 [PMID: 17229240 DOI: 10.1111/j.1365-2036.2006.03179.x]
11. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract 2013; 2013 : 236963 [PMID: 23653636 DOI: 10.1155/2013/236963]
12. Zhang Y, Lu J, Dai W, Wang F, Shen M, Yang J, Zhu R, Zhang H, Chen K, Cheng P, He L, Wang C, Xu L, Zhou Y, Guo C. Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 490731 [PMID: 24369456]
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797 DOI: 10.1016/0197-2456(95)00134-4]
14. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989 [PMID: 11730399 DOI: 10.7326/0003-4819-135-11-200112040-00010]
15. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol 2014; 7: 4-13 [PMID: 24381643 DOI: 10.1177/1756283X13503514]
16. Medeiros JA, Gonçalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011; 30: 555-559 [PMID: 21207091 DOI: 10.1007/s10096-010-1119-4]
17. Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15: 206-213 [PMID: 20557362 DOI: 10.1111/j.1523-5378.2010.00751.x]
18. Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18 : 6302-6307 [PMID: 23180952 DOI: 10.3748/wjg.v18.i43.6302]
19. Deguchi R, Nakaminami H, Rimbara E, Noguchi N, Sasatsu M, Suzuki T, Matsushima M, Koike J, Igarashi M, Ozawa H, Fukuda R, Takagi A. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 2012; 27: 888-892 [PMID: 22098133 DOI: 10.1111/j.1440-1746.2011.06985.x]
20. Mirzaee V, Rezahosseini O. Randomized control trial: Comparison of Triple Therapy plus Probiotic Yogurt vs. Standard Triple Therapy on Helicobacter Pylori Eradication. Iran Red Crescent Med J 2012; 14: 657-666 [PMID: 23285418]
21. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14 : 1625-1629 [PMID: 11121911 DOI: 10.1046/j.1365-2036.2000.00885.x]
22. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004; 20: 1181-1188 [PMID: 15569121 DOI: 10.1111/j.1365-2036.2004.02274.x]
23. Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD. Impact of supplement with Lactobacillus- and Bifidobacte-rium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-1675 [PMID: 12197847 DOI: 10.1046/j.1365-2036.2002.01335.x]
24. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21: 1263-1272 [PMID: 15882248 DOI: 10.1111/j.1365-2036.2005.02448.x]
25. Yaşar B, Abut E, Kayadibi H, Toros B, Sezikli M, Akkan Z, Keskin Ö, Övünç Kurdaş O. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol 2010; 21: 212-217 [PMID: 20931422 DOI: 10.4318/tjg.2010.0090]
26. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-268 [PMID: 18665934 DOI: 10.1111/j.1523-5378.2008.00601.x]
27. Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 2008; 12: 251-256 [PMID: 18727457]
28. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized place-bo-controlled double-blind study. Helicobacter 2007; 12: 309-316 [PMID: 17669103 DOI: 10.1111/j.1523-5378.2007.00516.x]
29. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut 1999; 45: 804-811 [PMID: 10562576 DOI: 10.1136/gut.45.6.804]
30. Tokunaga Y, Shirahase H, Hoppou T, Kitaoka A, Tokuka A, Ohsumi K. Density of Helicobacter pylori infection evaluated semiquantitatively in gastric cancer. J Clin Gastroenterol 2000; 31: 217-221 [PMID: 11034000 DOI: 10.1097/00004836-200010000-00006]
31. Fuller R. Probiotics in human medicine. Gut 1991; 32: 439
32. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130: 396S-402S [PMID: 10721914]
33. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16: 2202-2222 [PMID: 20458757 DOI: 10.3748/wjg.v16.i18.2202]
34. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137: 812S-818S [PMID: 17311980]
35. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-1475 [PMID: 16863547 DOI: 10.1111/j.1572-0241.2006.00717.x]
36. Bühling A, Radun D, Müller WA, Malfertheiner P. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 2001; 15: 1445-1452 [PMID: 11552917 DOI: 10.1046/j.1365-2036.2001.01033.x]
37. Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of Helicobacter pylori infection--a brief review. J Microbiol Immunol Infect 2014; 47 : 429-437 [PMID: 23757373 DOI: 10.1016/j.jmii.2013.03.010]